

Re Amended A / #15  
J 2/6/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

Andreas MENRAD et al.

Serial No.: 09/942,117

Filed: August 30, 2001



Group Art Unit

Examiner: Unassigned

For: RECEPTOR OF THE ED<sub>b</sub>-FIBRONECTIN DOMAINS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

*Please amend the claims as follows:*

3. (Amended) A protein, according to claim 1,
- a) that has the ability to bind specifically to the ED<sub>b</sub>-fibronectin domains and that comprises the  $\alpha 2\beta 1$  chain of the integrin;
  - b) that is expressed or activated specifically in endothelial cells;
  - c) that is expressed or activated specifically in stromal cells of a tumor;
  - d) that is expressed or activated specifically in tumor cells;
  - e) whose binding to the ED<sub>b</sub>-fibronectin domains is inhibited by a polypeptide and that comprises the  $\alpha$  chain of the integrin; and
  - f) that has an apparent molecular weight of 120-130 kDa for the light chain and 150-160 kDa for the heavy chain, determined by SDS-polyacrylamide gel electrophoresis.

0942117-12701

A1  
AC